Impact of cytosolic aldehyde oxidase contamination in liver microsomes on intrinsic clearance estimations
Drug Metabolism and Disposition · 2025
DOI: 10.1016/j.dmd.2025.100114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Lloyd Wei Tat Tang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc, Groton, Connecticut. Electronic address: lloydweitat.tang@pfizer.com. Hauptthemen laut MEDLINE: Microsomes, Liver, Aldehyde Oxidase, Cytosol. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
Several reports in the scientific literature characterize cytosolic aldehyde oxidase (AO) contamination in commercially available human liver microsomal preparations; however, the precise ramifications of residual AO activity on pharmacokinetic predictions remains unclear. In this study, we measured the rate of carbazeran 4-oxidation in 46 pairs of donor-matched microsomes and cytosol. Although a wide range of AO activity was observed across donors, the normalized (microsomal/cytosolic) AO activity was relatively consistent across all 46 donors, with a median activity of 36%. Furthermore, a highly significant linear relationship (P < .0001; R2 = 0.747) and strong rank correlation (ρ = 0.855) was observed between carbazeran 4-oxidation rates in donor-matched liver microsomes and cytosol. Taken together, these findings demonstrate that interindividual variability in hepatic AO activity is the key determinant for the varying levels of residual AO activity in liver microsomes. To evaluate whether cytosolic AO contamination in liver microsomes could confound intrinsic clearance estimates of AO substrates, we conducted a microsomal stability assay using liver microsomes from 3 donors with low (H0751), moderate (H0556), and high (H0544) residual AO activity. Carbazeran, O6-benzylguanine, and zaleplon were used as representative AO substrates with high, moderate, and low in vivo clearance, respectively. Our results suggest that cytosolic AO contamination primarily impacts substrate depletion intrinsic clearance estimates for substrates with high AO clearance, but not those with moderate or low AO clearance, due to the apparent lack of turnover of O6-benzylguanine and zaleplon across all 3 batches of liver microsomes. SIGNIFICANCE STATEMENT: Our study underscores interindividual variability in hepatic aldehyde oxidase (AO) activity as the key determinant underlying residual AO activity in liver microsomes and illuminated the potential impact of cytosolic AO contamination on the reliability of intrinsic clearance estimates-emphasizing the need for substrate-specific strategies and refined in vitro methodologies in drug metabolism studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc, Groton, Connecticut. Electronic address: lloydweitat.tang@pfizer.com.
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc, Groton, Connecticut.
Förderung
- Pfizer
Zitieren
APA
Tang, L. W. T., & Obach, R. S. (2025). Impact of cytosolic aldehyde oxidase contamination in liver microsomes on intrinsic clearance estimations. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100114
Vancouver
Tang LWT, Obach RS. Impact of cytosolic aldehyde oxidase contamination in liver microsomes on intrinsic clearance estimations. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100114
BibTeX
@article{Tang2025,
author = {Tang, Lloyd Wei Tat and Obach, R Scott},
title = {Impact of cytosolic aldehyde oxidase contamination in liver microsomes on intrinsic clearance estimations},
journal = {Drug Metabolism and Disposition},
year = {2025},
doi = {10.1016/j.dmd.2025.100114}
}
EUVIMED